Pharmaceuticals China

China Chronic Urticaria Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

China Chronic Urticaria Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $320.8 Mn Placeholder estimate
Estimate 2025 $351.9 Mn 8.6% of the global market
Projected 2034 $809.6 Mn 130.1% Adds $457.7 Mn over 9 forecast years
CAGR 2025–2034 9.7% Faster than 52% of 180 Pharmaceuticals markets here
Key players 5
  • China is 8.62% of the global market.
  • In APAC, the largest is China (this report) at $351.9 Mn.
  • Fastest growing: India at 11.1% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$457.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Chronic Urticaria Treatment Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $320.8 Mn — —
2025 (base) $351.9 Mn +$31.1 Mn —
2026 (forecast) $386.0 Mn +$34.1 Mn +9.7%
2027 (forecast) $423.5 Mn +$37.4 Mn +20.3%
2028 (forecast) $464.5 Mn +$41.1 Mn +32%
2029 (forecast) $509.6 Mn +$45.1 Mn +44.8%
2030 (forecast) $559.0 Mn +$49.4 Mn +58.9%
2031 (forecast) $613.2 Mn +$54.2 Mn +74.3%
2032 (forecast) $672.7 Mn +$59.5 Mn +91.2%
2033 (forecast) $738.0 Mn +$65.3 Mn +109.7%
2034 (forecast) $809.6 Mn +$71.6 Mn +130.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Chronic Urticaria Treatment Market Analysis at a glance
Market size, 2025$351.9 Mn placeholder estimate
Forecast, 2034$809.6 Mn placeholder estimate
Growth (CAGR), 2025–20349.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, type and end user (see all)
Key playersNovartis AG, Sanofi, Regeneron Pharmaceuticals, Celldex Therapeutics, Roche (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials20 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Chronic Urticaria Treatment Market Analysis Executive Summary

Chronic urticaria treatments control long-lasting hives and itching that do not go away with standard antihistamines.

Key segments of the chronic Urticaria Treatment market include drug class (Antihistamines, Anti-IgE Biologics and BTK Inhibitors) and type (Chronic Spontaneous Urticaria and Chronic Inducible Urticaria).

Bar chart: China Chronic Urticaria Treatment market size, 2024–2034, placeholder estimates. $320.8 Mn in 2024, $351.9 Mn in 2025 and $809.6 Mn in 2034, 9.7% CAGR.
China Chronic Urticaria Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Chronic Urticaria Treatment Market Dynamics

Market Growth Drivers

More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the chronic Urticaria Treatment market. Biosimilars are widening access.

Opportunity

New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the chronic Urticaria Treatment market room to grow.

Market Restraints

High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the chronic Urticaria Treatment market.

Competitive Landscape for Chronic Urticaria Treatment Market in China

The chronic Urticaria Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Chronic Urticaria Treatment Market in China

Chronic Urticaria Treatment in China: rules, payment and research

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 20 studies on Chronic Urticaria Treatment that are recruiting, active or about to start in China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for chronic Urticaria Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Chronic Urticaria Treatment right now, from free public sources.

Clinical trials

20 active trials in China

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Novartis AG 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Hangzhou Highlightll Pharmaceutical Co., Ltd 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Celldex Therapeutics 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Shanghai Mabgeek Biotech.Co.Ltd 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Jemincare 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Chronic Urticaria Treatment in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Chronic Urticaria Treatment market in China?
Placeholder estimate: about $351.9 Mn in 2025, rising to about $809.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Chronic Urticaria Treatment market in China growing?
Placeholder estimate: about 9.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Chronic Urticaria Treatment market report cover?
The report splits the market by drug class (Antihistamines, Anti-IgE Biologics, BTK Inhibitors, Others), type (Chronic Spontaneous Urticaria, Chronic Inducible Urticaria) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Chronic Urticaria Treatment market?
Key players include Novartis AG, Sanofi, Regeneron Pharmaceuticals, Celldex Therapeutics and Roche.
What is driving the Chronic Urticaria Treatment market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the chronic Urticaria Treatment market. Biosimilars are widening access.
Who regulates Chronic Urticaria Treatment in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Chronic Urticaria Treatment are running in China?
20 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Chronic Urticaria Treatment?
PubMed lists 677 papers on Chronic Urticaria Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on allergies and skin and hair

See the topic